Quick Answer
Armata Pharmaceuticals, Inc. reported Diluted EPS of $4.80 per share (loss) for fiscal year 2025.
Armata Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.80 | -439.3% |
| 2024 | -$0.89 | +53.4% |
| 2023 | -$1.91 | -76.9% |
| 2022 | -$1.08 | -12.5% |
| 2021 | -$0.96 | +28.9% |
| 2020 | -$1.35 | +47.1% |
| 2019 | -$2.55 | +29.0% |
| 2018 | -$3.59 | -64.7% |
| 2017 | -$2.18 | +91.2% |
| 2016 | -$24.67 | -1139.7% |
| 2015 | -$1.99 | +14.6% |
| 2014 | -$2.33 | -264.1% |
| 2013 | -$0.64 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.74 | -393.3% | -64.4% |
| June 30, 2025 | -$0.45 | -80.0% | -125.0% |
| March 31, 2025 | -$0.20 | +71.0% | -33.3% |
| September 30, 2024 | -$0.15 | +82.6% | +40.0% |
| June 30, 2024 | -$0.25 | -47.1% | +63.8% |
| March 31, 2024 | -$0.69 | -72.5% | +19.8% |
| September 30, 2023 | -$0.86 | -258.3% | -405.9% |
| June 30, 2023 | -$0.17 | +34.6% | +57.5% |
- Armata Pharmaceuticals, Inc. showed a decrease of -439.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2013–2025 period, Armata Pharmaceuticals, Inc.’s diluted eps has declined by 650.0% (from $0.64 per share (loss) to $4.80 per share (loss)).
- The most recent figure is from Armata Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: